Trial Profile

Etanercept Leads to Smooth Suppression of Inflammation in SpA (the ELSSI study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary)
Indications Ankylosing spondylitis
Focus Therapeutic Use
Acronyms ELSSI

Most Recent Events

11 Jul 2016 Status changed from recruiting to completed.
28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 30 Jun 2016 Accrual to Date is 73% according to the United Kingdom Clinical Research Network record.
28 Jan 2016 Accrual to Date is 77% according to the United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com